GlassScriptPhysician profile
Emily G Robb
NPI 1689780082
$4,444.89
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $109 · 2021: $636 · 2022: $1,575 · 2023: $1,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $635.42 | 2019-2023 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $456.85 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $372.74 | 2020-2023 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $283.60 | 2019-2023 | Farxiga, Evusheld |
| Amgen INC. | $246.24 | 2019-2023 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $234.42 | 2019-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $203.74 | 2022-2023 | |
| Abbott Laboratories | $188.99 | 2022-2023 | Freestyle Libre 2, Proclaim |
| Glaxosmithkline, LLC. | $131.79 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Antares Pharma, INC. | $118.76 | 2019-2023 | Xyosted, Nocdurna, Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.67 | 2022-2023 | Jardiance |
| Pfizer INC. | $111.61 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.37 | 2019-2022 | |
| Adlon Therapeutics L.P. | $92.07 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $86.24 | 2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Robb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.